BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
Arlo Technologies has registered over 4.2 million shares for an employee stock plan, a move that brings potential dilution and the company's capital strategy into focus as its stock shows signs of cooling momentum after a strong run.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
NAPCO Security Technologies (NSSC) reported strong fiscal second-quarter results, with record revenue and expanding profitability. The company highlighted the sustained momentum of its high-margin recurring service model and announced a dividend increase.
German biotech firm AMSilk partners with Italian mill Pure Denim to launch a new category of high-performance, sustainable denim infused with lab-grown spider silk proteins, targeting the luxury market with enhanced comfort and eco-credentials.
Recent financial disclosures reveal significant repositioning by Speaker Emerita Nancy Pelosi and her husband in tech giants Nvidia, Apple, and Alphabet, sparking investor interest in their strategy of locking in gains while maintaining bullish exposure.
Ark Invest's founder bolstered positions in key holdings across e-commerce, fintech, and cryptocurrency sectors ahead of major earnings reports, signaling confidence amidst market volatility.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Investment firm Ashva Capital Management reveals Micron Technology as its largest holding in its latest investor letter, detailing a conviction play on the memory chip giant's long-term trajectory amid AI-driven demand and market volatility.
A recent anniversary event for 'Silicon Alley' highlighted how New York's technology sector has evolved from a concentrated downtown community into a vast, decentralized force spanning finance, AI, and e-commerce.
After a prolonged correction, Brent crude oil is showing signs of a potential trend reversal, with a forming double bottom pattern pointing toward a technical target near $95 per barrel. The shift comes amid a tightening physical market and simmering geopolitical risks.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
Schweiter Technologies (SWTQ) has seen significant price swings on the SIX Swiss Exchange. With its current valuation trading well above industry peers, we examine whether the stock's optimistic growth prospects justify the premium or if investors should wait for a better entry point.
Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
With its stock down 30% over the past year and a fresh 3.5% drop last week, Marvell Technology faces mounting pressure from its powerful institutional base, which controls 81% of the company. Analysts warn that continued underperformance could trigger a wave of selling, impacting all investors.
Despite a 35% monthly plunge, Hedera's HBAR shows signs of underlying buyer interest through key technical divergences. However, a critical shift in exchange flows threatens to delay any near-term price rebound, leaving the token at a pivotal juncture.
While many chase high-risk, loss-making stories, Tyler Technologies (TYL) stands out with consistent profitability and growth. We examine the key metrics and management alignment that make this software provider a stock worth watching.
